Xylem affirms Q3 adjusted EPS and sales guidance ranges
Xylem (NYSE: XYL) affirms Q3 adjusted EPS guidance of $1.42-$1.47 versus a $1.46 analyst estimate and maintains Q3 sales outlook at $2.300 billion versus $2.316 billion expected.
Xylem (NYSE: XYL ) affirms Q3 Adj EPS guidance from $1.42-$1.47 to $1.42-$1.47 vs $1.46 analyst estimate.
Affirms Q3 sales outlook from $2.300 billion to $2.300 billion vs $2.316 billion estimate.